title: Development of acute lymphoblastic leukemia following hemophagocytic lymphohistiocytosis: is it secondary leukemia?
authors.forename: T
authors.initials: T
authors.lastname: Suzuki
authors.forename: H
authors.initials: H
authors.lastname: Mugishima
authors.forename: A
authors.initials: A
authors.lastname: Yamada
authors.forename: T
authors.initials: T
authors.lastname: Nagata
authors.forename: H
authors.initials: H
authors.lastname: Shichino
authors.forename: M
authors.initials: M
authors.lastname: Chin
authors.forename: S
authors.initials: S
authors.lastname: Imashuku
authors.forename: K
authors.initials: K
authors.lastname: Harada
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic; D002675:Child, Preschool; D003907:Dexamethasone / Q000009:adverse effects / Q000627:therapeutic use; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D015616:Histiocytosis, Non-Langerhans-Cell / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000139:chemically induced / Q000209:etiology*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide; D003907:Dexamethasone